Procter & Gamble Health Limited (PGHL.NS)
INR 5467.25
(0.04%)
INR 5467.25
(0.04%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.56 Billion INR | -26.89% |
| 2022 | 3.5 Billion INR | 26.36% |
| 2021 | 2.77 Billion INR | -1.85% |
| 2020 | 2.82 Billion INR | 4.6% |
| 2019 | 2.7 Billion INR | 23.11% |
| 2018 | 2.19 Billion INR | -14.97% |
| 2017 | 2.57 Billion INR | 8.67% |
| 2016 | 2.37 Billion INR | 23.36% |
| 2015 | 1.92 Billion INR | 25.01% |
| 2014 | 1.53 Billion INR | 22.57% |
| 2013 | 1.25 Billion INR | 13.53% |
| 2012 | 1.1 Billion INR | 23.53% |
| 2011 | 895.4 Million INR | 7.16% |
| 2010 | 835.6 Million INR | -17.16% |
| 2009 | 1 Billion INR | -7.58% |
| 2008 | 1.09 Billion INR | 63.8% |
| 2007 | 666.3 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 FY | 2.56 Billion INR | -26.89% |
| 2023 Q4 | 2.56 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 2.71 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 3.5 Billion INR | 26.36% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 3.5 Billion INR | 0.0% |
| 2022 Q2 | 3.45 Billion INR | 0.0% |
| 2021 Q4 | 2.77 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 2.61 Billion INR | 0.0% |
| 2021 FY | 2.77 Billion INR | -1.85% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q2 | 2.06 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 2.82 Billion INR | 0.0% |
| 2020 FY | 2.82 Billion INR | 4.6% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q4 | 2.27 Billion INR | 0.0% |
| 2019 FY | 2.7 Billion INR | 23.11% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 2.19 Billion INR | -14.97% |
| 2018 Q2 | 2.19 Billion INR | 0.0% |
| 2018 Q4 | 2.29 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 2.57 Billion INR | 8.67% |
| 2017 Q4 | 2.53 Billion INR | 0.0% |
| 2017 Q2 | 2.57 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 2.27 Billion INR | 0.0% |
| 2016 FY | 2.37 Billion INR | 23.36% |
| 2016 Q2 | 2.37 Billion INR | 0.0% |
| 2015 FY | 1.92 Billion INR | 25.01% |
| 2015 Q4 | 1.9 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 1.92 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 1.53 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 1.53 Billion INR | 22.57% |
| 2014 Q4 | 1.83 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 FY | 1.25 Billion INR | 13.53% |
| 2013 Q2 | 1.25 Billion INR | 0.0% |
| 2013 Q4 | 1.37 Billion INR | 0.0% |
| 2012 FY | 1.1 Billion INR | 23.53% |
| 2012 Q2 | 1.1 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q4 | 1.27 Billion INR | 0.0% |
| 2011 FY | 895.4 Million INR | 7.16% |
| 2011 Q2 | 895.4 Million INR | 0.0% |
| 2011 Q4 | 1.99 Billion INR | 0.0% |
| 2010 FY | 835.6 Million INR | -17.16% |
| 2009 FY | 1 Billion INR | -7.58% |
| 2008 FY | 1.09 Billion INR | 63.8% |
| 2007 FY | 666.3 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Sigachi Industries Limited | 2.53 Billion INR | -1.183% |
| Ind-Swift Limited | 13.45 Billion INR | 80.962% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 47.383% |
| Sakar Healthcare Limited | 1.26 Billion INR | -102.742% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 98.317% |
| Innova Captab Limited | 4.89 Billion INR | 47.729% |
| Divi's Laboratories Limited | 18.99 Billion INR | 86.513% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | 30.043% |
| Morepen Laboratories Limited | 4.45 Billion INR | 42.571% |
| Mankind Pharma Limited | 23.87 Billion INR | 89.272% |
| Sequent Scientific Limited | 8.27 Billion INR | 69.046% |
| Wanbury Limited | 3.15 Billion INR | 18.834% |
| Laurus Labs Limited | 42.71 Billion INR | 94.004% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 77.169% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 50.565% |
| Alembic Limited | 1.43 Billion INR | -78.842% |
| Hikal Limited | 12.99 Billion INR | 80.291% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 84.262% |
| Neuland Laboratories Limited | 5.49 Billion INR | 53.421% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 76.081% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 96.066% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 59.532% |
| Themis Medicare Limited | 1.88 Billion INR | -35.692% |
| RPG Life Sciences Limited | 1.38 Billion INR | -85.567% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 96.432% |
| Lupin Limited | 96.23 Billion INR | 97.339% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -226.757% |
| Wockhardt Limited | 39.87 Billion INR | 93.576% |
| Vaishali Pharma Limited | 371.16 Million INR | -590.047% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 68.958% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -763.054% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 95.82% |
| FDC Limited | 3.7 Billion INR | 30.95% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 97.606% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -297.774% |
| Eris Lifesciences Limited | 38.26 Billion INR | 93.307% |
| Venus Remedies Limited | 1.39 Billion INR | -83.889% |
| ZIM Laboratories Limited | 2.08 Billion INR | -23.09% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -21.45% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -1502.844% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | 26.94% |
| Shilpa Medicare Limited | 12.93 Billion INR | 80.196% |
| Albert David Limited | 1.15 Billion INR | -122.693% |
| Ajanta Pharma Limited | 10.71 Billion INR | 76.087% |
| Hester Biosciences Limited | 3.59 Billion INR | 28.751% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -25.905% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 81.825% |
| Gufic Biosciences Limited | 5.59 Billion INR | 54.263% |
| Windlas Biotech Limited | 1.76 Billion INR | -45.3% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -48.718% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -29.595% |
| Granules India Limited | 22.95 Billion INR | 88.842% |
| Aarti Drugs Limited | 11.5 Billion INR | 77.736% |
| Bal Pharma Limited | 2.51 Billion INR | -1.988% |
| Alkem Laboratories Limited | 48.6 Billion INR | 94.731% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 98.605% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -138.352% |
| Medicamen Biotech Limited | 940.36 Million INR | -172.362% |
| Unichem Laboratories Limited | 8.06 Billion INR | 68.26% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -292.654% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -786.845% |
| Valiant Laboratories Limited | 1.05 Billion INR | -142.02% |
| Orchid Pharma Limited | 3.84 Billion INR | 33.373% |
| Medico Remedies Limited | 438.24 Million INR | -484.423% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -11.869% |
| Ipca Laboratories Limited | 33.74 Billion INR | 92.41% |
| Brooks Laboratories Limited | 248.6 Million INR | -930.245% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -119.806% |
| Piramal Enterprises Limited | 560.47 Billion INR | 99.543% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 96.878% |
| NATCO Pharma Limited | 10.53 Billion INR | 75.682% |
| Suven Life Sciences Limited | 148.62 Million INR | -1623.31% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 13.878% |
| Strides Pharma Science Limited | 37.68 Billion INR | 93.203% |
| Indoco Remedies Limited | 10.34 Billion INR | 75.236% |
| Alpa Laboratories Limited | 307.12 Million INR | -733.936% |
| Lasa Supergenerics Limited | 541.92 Million INR | -372.612% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 34.208% |